Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05466799
An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.
Overview
The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer
Sponsor
OncoSil Medical Limited
Phase
Phase 2
Contacts
Henk Tissing
henk.tissing@oncosil.com
+31651384883
Tom Maher
tom.maher@oncosil.com
ClinicalTrials.gov
NCT05466799Drug / Compound
Isotope(s):
PHOSPHORUS-32
Radioisotope: P-32
Theranostic Role: Therapeutic Agent, SPECT Imaging
T1/2 (Half-Life): 14.3 Days
Decay Mode: BETA
Energy: Max: 1.71 MeV, Avg: 694 keV
Range: Air: 20 feet, Water/Tissue: 8.7mm
Decay Daughters: S32 (Stable)
Status: Clinical Trials Only
Target(s):
Share your feedback
Help us improve your experience